Skip to content

SOFGEN PHARMA, S.A.

CIK 0001863362

← back to feed
Revenue (TTM)
$373.8M
−11.8% YoY FY Dec 2024
Net Income (TTM)
−$68.3M
−269.3% YoY FY Dec 2024
EPS Diluted (TTM)
−$0.68
−270.0% YoY FY Dec 2024
Gross Margin
51.2%
FY Dec 2024
Operating Margin
-14.4%
FY Dec 2024
Net Margin
-18.3%
FY Dec 2024
Free Cash Flow (TTM)
—
FY Dec 2024
Cash
$30.32M
FY Dec 2024
Total Debt
—
FY Dec 2024
Shares Outstanding
112.82M sh
FY Dec 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings